Try our Advanced Search for more refined results

Expert Analysis

Issues To Watch In Fed. Circ. Hep C Drug Patent Case

By Robert Scheffel and Matthew Dowd (June 7, 2019, 3:10 PM EDT) -- In a fully briefed appeal scheduled for oral argument on July 9, 2019, the U.S. Court of Appeals for the Federal Circuit will again address the issue of enablement but in an area it rarely wades — the enablement of patent claims directed to a chemical genus defined by chemical structure. The case, Idenix Pharmaceuticals LLC v. Gilead Sciences Inc., may significantly alter patent practice in the chemical arts. ...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Read the full article

Already a subscriber? Click here to login

Related Sections

Law Firms

Companies

Government Agencies

Patents

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!